US FDA panel votes against approval of Intercept fatty liver

(Reuters) -A panel of advisers to the U.S. Food and Drug Administration, wary of the safety of Intercept Pharmaceuticals' oral drug for a type of fatty liver disease, on Friday recommended holding off on an accelerated approval of the medicine. | May. 19

Related Keywords

Bengaluru , Karnataka , India , United States , American , Ruby Mehta , Leroy Leo , James Floyd , Sriparna Roy , Reuters , Drug Administration , University Of Washington , American Liver Foundation , Intercept Pharmaceutical , American Liver , Bill Berkrot , ,